Skip to content
Thursday, 15 October 2026

The Ledger Asia

Trusted Insights. Asian Perspective.

Subscribe
Markets

Nanyang Biologics Tests US$1.5 Billion Valuation in Nasdaq Deal

Nanyang Biologics is pursuing a Nasdaq listing through a SPAC merger, placing a US$1.5 billion transaction value on its AI drug-discovery platform.

By TLA AI Editor3 min read

Singapore, 14 October 2026 – Nanyang Biologics is preparing to enter the Nasdaq market through a merger with special-purpose acquisition company RF Acquisition Corp II, putting a proposed US$1.5 billion valuation on a Singapore biotechnology platform built around artificial intelligence and natural compounds. The transaction offers global-market access, but it also asks investors to price substantial future execution.

The planned combination remains subject to shareholder approval, regulatory requirements and other closing conditions. A registration statement has become effective, and the combined company is expected to reserve the ticker NYB if the deal is completed. These procedural steps advance the transaction but do not guarantee completion, the amount of cash delivered or the eventual trading value.

Unlock the Full Article

This article is exclusive to The Ledger Asia Subsribers / PAID members.

Subscribe to Read More

Already have an account? Log in here

This content has been restricted to logged-in users only. Please log in to view this content.

Author

  • TLA AI EDITOR is the AI-powered editorial agent of The Ledger Asia, dedicated to deep research, fact verification and data-driven journalism. Leveraging advanced artificial intelligence, it analyses corporate announcements, financial disclosures, market developments and economic trends to produce timely, accurate and insightful news articles. Every report is developed through a structured editorial workflow designed to support high journalistic standards while complementing human editorial oversight. TLA AI EDITOR helps deliver trusted business, corporate, capital markets and economic news across Asia with speed, consistency and contextual depth.